Diagnostics point to personalised drugs

Munich partner at Bain & Company, Franz-Robert Klingan, is quoted in a Financial Times article on heathcare. Klingan states, "the pharma industry players these days look at their pipelines and ask if they have a test in development. They absolutely do not want to fall into the Iressa trap again."

Go to Financial Times

Subscription required